Gyre Therapeutics, Inc.
GYRE
$6.13
$0.081.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.09% | 33.45% | 19.92% | 6.13% | -18.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.09% | 33.45% | 19.92% | 6.13% | -18.82% |
| Cost of Revenue | 37.25% | 48.09% | 69.94% | 49.48% | -8.68% |
| Gross Profit | 0.60% | 32.80% | 17.96% | 4.76% | -19.20% |
| SG&A Expenses | 35.20% | 36.72% | 12.13% | 12.25% | -0.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.20% | 36.26% | 11.21% | 12.00% | 3.58% |
| Operating Income | -399.25% | -81.90% | 63.62% | -33.42% | -71.84% |
| Income Before Tax | -299.29% | -108.55% | 94.12% | -62.92% | -62.86% |
| Income Tax Expenses | -31.08% | 540.39% | 57.64% | -55.78% | -64.61% |
| Earnings from Continuing Operations | -364.01% | -340.07% | 107.84% | -65.27% | -62.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 212.64% | 46.56% | -34.30% | -12.28% | 56.89% |
| Net Income | -422.13% | -1,640.40% | 221.17% | -87.47% | -64.18% |
| EBIT | -399.25% | -81.90% | 63.62% | -33.42% | -71.84% |
| EBITDA | -318.30% | -29.92% | 61.93% | -19.40% | -66.91% |
| EPS Basic | -405.13% | -1,475.00% | 203.05% | -87.89% | -65.52% |
| Normalized Basic EPS | -253.49% | -237.93% | 216.47% | -90.85% | -66.82% |
| EPS Diluted | -2,334.88% | -541.18% | 166.41% | -63.33% | -86.39% |
| Normalized Diluted EPS | -281.32% | -237.93% | 230.99% | -90.51% | -65.40% |
| Average Basic Shares Outstanding | 5.67% | 6.05% | 6.08% | 4.23% | 3.79% |
| Average Diluted Shares Outstanding | -10.42% | 6.05% | 1.30% | 0.49% | -0.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |